Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051675
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2003-01-14
Brief Title:
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Sponsor:
XOMA US LLC
Organization:
XOMA US LLC
Study Overview
Official Title:
An Open-Label Multi-Dose Phase I Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody ING-1heMAb in Subjects With Advanced Adenocarcinomas
Status:
COMPLETED
Status Verified Date:
2004-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety immunogenicity and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary breast lung prostate colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None